Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 369 of 6351
-
Dissolvable scaffolds could save legs from amputation in major new trial
Disease control Not yet recruitingRESCUE is a Europe-wide study that will follow 400 people with critical limb-threatening ischemia (CLTI). It aims to see how well Esprit BTK™ Everolimus Eluting Resorbable Scaffolds work in real-life medical settings. The study focuses on people who have heavily calcified arterie…
Sponsor: Cardiovascular and Interventional Radiological Society of Europe • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New stent could save limbs in critical leg artery disease
Disease control Not yet recruitingThe purpose of this trial is to evaluate the safety and efficacy of the Drug Eluting Temporary Spur Stent System compared to PTA. The Drug Eluting Temporary Spur Stent System is intended for use as a primary treatment in the infrapopliteal arteries for the treatment of de novo o…
Sponsor: ReFlow Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for Hard-to-Treat prostate cancer: drug combo trial launches
Disease control Not yet recruitingThe purpose of this study is to find out whether mevrometostat in combination with enzalutamide delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have previously received enzalutamide, darolutamide, or apalutamide in the metastat…
Phase 2 • Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a single iron infusion ease heart failure in seniors?
Disease control Not yet recruitingThis randomized, double-blind, placebo-controlled clinical trial evaluates intravenous ferric derisomaltose in older adults with HFpEF and iron deficiency.
Phase 4 • Sponsor: Duke University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Gene therapy for rare genetic syndrome moves to Long-Term safety check
Disease control By invitation onlyThis is a long-term follow-up study of participants in the RB001-101 gene replacement therapy clinical trial for Children With SHANK3-related Phelan-McDermid Syndrome (PMS). Participants will roll over from the parent study into this long-term study for continuous safety monitori…
Phase 1 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug duo targets Hard-to-Treat colorectal cancer
Disease control Not yet recruitingThe purpose of this study is find out whether the combination of trastuzumab deruxtecan (T-DXd) and cetuximab is an effective treatment for participants with metastatic and/or unresectable colorectal cancer that expresses low levels of HER2 and that has gotten worse after receivi…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Fewer radiation sessions may be just as effective for thymic tumors after surgery
Disease control Not yet recruitingThis is a multi-center, open-label, single-arm, prospective interventional study evaluating hypofractionated adjuvant radiotherapy (HART) after radical thymothymectomy in patients with thymic epithelial tumors. The study estimates 5-year local control and prospectively characteri…
Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
A common antioxidant may help platelets recover faster after stem cell transplant
Disease control Not yet recruitingThis study aims to evaluate the efficacy and safety of prophylactic oral N-acetylcysteine (NAC) for facilitating platelet engraftment in patients with severe aplastic anemia (SAA) receiving haploidentical hematopoietic stem cell transplantation (haplo-HSCT). This is a prospective…
Phase 3 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a wearable monitor prevent heart emergencies after valve replacement?
Disease control Not yet recruitingThis multicenter, prospective, randomized superiority trial will evaluate whether systematic 14-day ambulatory ECG monitoring following hospital discharge after transcatheter aortic valve implantation (TAVI) reduces the risk of sudden death, symptomatic arrhythmic events, or stro…
Sponsor: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can AI predict dangerous complications after aortic dissection repair?
Knowledge-focused Not yet recruitingThis study aims to establish a multicenter, prospective, observational registry database for type B aortic dissection based on approximately 60 regional sentinel hospitals across China. It develops a digital intelligent management system, formulates quality control indicators and…
Sponsor: Chang Shu • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Can a targeted antibody calm severe eczema?
Disease control Not yet recruitingThis first-in-human study evaluates BYN-001, a humanized IgG1 monoclonal antibody targeting interleukin-25 (IL-25), a cytokine implicated in atopic dermatitis. Parts A and B are randomized, double-blind, placebo-controlled single and multiple ascending dose cohorts in healthy adu…
Phase 1 • Sponsor: Bionyra Pharma • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Bone scans may reveal how breast cancer subtypes spread
Knowledge-focused Not yet recruitingThe goal of this observational study is to evaluate the association between different molecular subtypes of breast cancer and their specific patterns of skeletal metastases on Technetium-99m MDP bone scintigraphy. The study will include adult male and female patients aged 18 to …
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can a Dual-Pronged antibody outsmart advanced cancers?
Disease control Not yet recruitingThis study is an open-label, multicenter, dose-escalation and expansion, non-randomized Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036 bispecific antibody injection in patients with locally advanced …
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a rare mutation that blocks pain reveal new painkiller targets?
Knowledge-focused Not yet recruitingCongenital insensitivity to pain (CIP) comprises a group of rare genetic disorders caused by mutations in genes essential for pain sensing in humans. Among these, Marsili syndrome is caused by a dominant point mutation in the transcription factor ZFHX2, and it is characterized by…
Sponsor: Aalborg University • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Which nerve block eases rib fracture pain better?
Symptom relief Not yet recruitingRib fractures happen in about 10-20% of patients with blunt trauma and can be serious, with higher death rates in older adults. These injuries often lead to lung problems like pneumonia, collapsed lung areas (atelectasis), fluid buildup, or even respiratory failure. A major reaso…
Sponsor: Sunnybrook Health Sciences Centre • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Could everyday supplements turn back the clock on aging?
Prevention Not yet recruitingThe goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements. The main questions it aims to answer are: 1. Do Quercefi…
Sponsor: Applied Science & Performance Institute • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Can a new infusion drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis is an open-label, multicenter, non-randomized Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-ARC002 Injection in patients with locally advanced or metastatic solid tumors.
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Soothing sounds: a simple audio may help Low-Birth-Weight babies thrive
Symptom relief Not yet recruitingThe goal of this clinical trial is to learn if listening to a relaxation audiorecording during breastfeeding improves breastfeeding and infant outcomes and maternal well-being in a low-income country setting. The main questions it aims to answer are: * Does listening to a relaxa…
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
One iron shot vs. many: which fixes Post-Surgery anemia faster?
Disease control Not yet recruitingThis is a multicenter, open-label, randomized controlled trial. A total of 160 patients with iron-deficiency anemia after radical gastrectomy for gastric cancer will be enrolled and randomly assigned in a 1:1 ratio. Subjects in the experimental group will receive a single-dose in…
Phase 4 • Sponsor: Zhaojian Niu,MD • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Seaweed extract may soothe inflamed guts — trial puts it to the test
Disease control By invitation onlyWhat is the research question being addressed? Does combining Turbinaria ornata-derived fucoidan with standard therapy lead to a significantly higher rate of gut health restoration-defined by increased fecal short-chain fatty acid (butyrate/acetate) levels, reduced fecal calprote…
Phase 1/2 • Sponsor: Allama Iqbal Medical College • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC